【摘要】 目的 了解2012-2021年全国乙型病毒性肝炎(乙肝)病例重复报告情况，分析其对报告发病率的影响。方法 使用不同规则组合对2012-2021年全国乙肝报告发病病例进行个案查重并对个案进行唯一标识编码，分析重复报告情况。结果 2012-2021年乙肝累计报告发病10 673 608例，共查出1 031 713例重复报告病例，重复报告率为9.67%。年度重复报告率呈上升趋势(χ~2=339 079.188,P<0.001),2021年重复报告率最高(16.26%);年内平均重复报告率为1.84%。各省份重复报告率在3.44%～18.22%之间，重卡率最低的3个省份为北京市(3.44%)、天津市(3.55%)和浙江省(3.96%);随年龄组增加重复报告率呈上升趋势(χ~2=52 779.96,P<0.001);医院中三级医院的重复报告构成比(52.44%)和重报率(11.72%)均最高。2012-2021年全国乙肝年均发病率为77.52/10万，删除重复报告后年均发病率为70.03/10万。结论 2012-2021年全国乙肝重复报告率为9.67%,重复报告一定程度影响着对乙肝真实流行情况的评估，应当探索适合于乙肝疫情监测管理的新机制。更多还原

【Abstract】 Objective To investigate the repetitive reporting of hepatitis B cases in China from 2012 to 2021, and analyze its impact on the reported morbidity.Methods Different combinations of rules were used to check the duplicate cases of hepatitis B reported in China from 2012 to 2021 and these cases were uniquely encoded to analyze the duplicated reports.Results During 2012-2021, a total of 10 673 608 hepatitis B cases were reported, and 1 031 713 cases of repetitive reports were detected, with a duplicated reporting rate of 9.67%. The rate of annual duplicated reporting showed an upward trend(χ~2=339 079.188,P<0.001), with the highest duplicate reporting rate in 2021(16.26%). The annual average duplicated reporting rate was 1.84%. The duplicated reporting rate of each province ranged from 3.44% to 18.22%, and the three provinces with the lowest duplicated reporting rate were Beijing(3.44%), Tianjin(3.55%) and Zhejiang(3.96%); The rate of duplicated reporting increased with the age group(χ~2= 52 779.96,P<0.001); The proportion of duplicated reporting(52.44%) and the rate of duplicated reporting(11.72%) in tertiary hospitals were the highest. The average annual incidence rate of hepatitis B in China from 2012 to 2021 was 77.52/100 000, and 70.03/100 000 after the deleting of duplicate reports.Conclusions During 2012-2021, the duplicated reporting rate of hepatitis B in China was 9.67%. To a certain extent, the duplicated reporting affected the assessment of the real epidemic situation of hepatitis B. New mechanisms suitable for the monitoring and management of hepatitis B should be explored.更多还原